MicroRNA‑598 inhibits the proliferation and invasion of non‑small cell lung cancer cells by directly targeting ZEB2 Retraction in /10.3892/etm.2022.11455

Tong,Xiangdong; Su,Peng; Yang,Haitao; Chi,Fusheng; Shen,Lin; Feng,Xiao; Jiang,Hongqian; Zhang,Xiuchun; Wang,Zhenyuan

doi:10.3892/etm.2018.6825

MicroRNA‑598 inhibits the proliferation and invasion of non‑small cell lung cancer cells by directly targeting ZEB2

Retraction in: /10.3892/etm.2022.11455

Authors:
- Xiangdong Tong
- Peng Su
- Haitao Yang
- Fusheng Chi
- Lin Shen
- Xiao Feng
- Hongqian Jiang
- Xiuchun Zhang
- Zhenyuan Wang
View Affiliations

Affiliations: Department of Thoracic Surgery, The People's Hospital of Liaoning Province, Shenyang, Liaoning 110016, P.R. China, Department of Thoracic Surgery, Liaoyang City Central Hospital, Liaoning 111000, P.R. China
Published online on: October 3, 2018 https://doi.org/10.3892/etm.2018.6825
Pages: 5417-5423

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An increasing number of studies have observed that microRNAs (miRNAs) are abnormally expressed in non‑small cell lung cancer (NSCLC), and that their aberrant expression links with the progression and development of NSCLC. Therefore, it is necessary to full elucidate the specific roles of miRNAs in NSCLC, as this may facilitate the identification of novel therapeutic targets. In the present study, it was observed that miRNA‑598 (miR‑598) expression was significantly downregulated in NSCLC tissues and cell lines. Decreased miR‑598 was negatively correlated with TNM stage and lymph node metastasis in NSCLC patients. In addition, ectopic expression of miR‑598 reduced NSCLC cell proliferation and invasion in vitro. The zinc finger E‑box‑binding homeobox 2 (ZEB2) was validated as a direct target of miR‑598 in NSCLC cells. ZEB2 was upregulated in NSCLC tissues and the upregulation of ZEB2 was inversely correlated with the miR‑598 level. The results revealed that restored ZEB2 expression abrogated the inhibitory effects of miR‑598 overexpression in NSCLC cells. In conclusion, the results of the present study revealed that miR‑598 may inhibit the progression of NSCLC by directly targeting ZEB2, which suggests that this miRNA may be identified as a potential novel prognostic biomarker and therapeutic target for patients with NSCLC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Laskin JJ and Sandler AB: State of the art in therapy for non-small cell lung cancer. Cancer Invest. 23:427–442. 2005. View Article : Google Scholar : PubMed/NCBI
3	Subramaniam S, Thakur RK, Yadav VK, Nanda R, Chowdhury S and Agrawal A: Lung cancer biomarkers: State of the art. J Carcinog. 12:32013. View Article : Google Scholar : PubMed/NCBI
4	Boffetta P and Nyberg F: Contribution of environmental factors to cancer risk. Br Med Bull. 68:71–94. 2003. View Article : Google Scholar : PubMed/NCBI
5	Ridge CA, McErlean AM and Ginsberg MS: Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98. 2013. View Article : Google Scholar : PubMed/NCBI
6	Zhang Y, Wang Y and Wang J: MicroRNA-584 inhibits cell proliferation and invasion in non-small cell lung cancer by directly targeting MTDH. Exp Ther Med. 15:2203–2211. 2018.PubMed/NCBI
7	Ramalingam SS, Owonikoko TK and Khuri FR: Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
8	Xu G, Shao G, Pan Q, Sun L, Zheng D, Li M, Li N, Shi H and Ni Y: MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting eukaryotic translation initiation factor 5A2. Am J Transl Res. 9:478–488. 2017.PubMed/NCBI
9	National Lung Screening Trial Research Team, . Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, et al: The National Lung Screening Trial: Overview and study design. Radiology. 258:243–253. 2011. View Article : Google Scholar : PubMed/NCBI
10	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
11	Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
12	Behm-Ansmant I, Rehwinkel J and Izaurralde E: MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI
13	Castro D, Moreira M, Gouveia AM, Pozza DH and De Mello RA: MicroRNAs in lung cancer. Oncotarget. 8:81679–81685. 2017. View Article : Google Scholar : PubMed/NCBI
14	Vannini I, Fanini F and Fabbri M: Emerging roles of microRNAs in cancer. Curr Opin Genet Dev. 48:128–133. 2018. View Article : Google Scholar : PubMed/NCBI
15	Ramassone A, Pagotto S, Veronese A and Visone R: Epigenetics and MicroRNAs in Cancer. Int J Mol Sci. 19(pii): E4592018. View Article : Google Scholar : PubMed/NCBI
16	Xia H, Li Y and Lv X: MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer. Int J Oncol. 49:1325–1333. 2016. View Article : Google Scholar : PubMed/NCBI
17	Zang H, Peng J, Wang W and Fan S: Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer. J Cancer. 8:3856–3861. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zhou Q, Huang SX, Zhang F, Li SJ, Liu C, Xi YY, Wang L, Wang X, He QQ, Sun CC and Li DJ: MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer. Cell Prolif. 50:2017. View Article : Google Scholar
19	Florczuk M, Szpechcinski A and Chorostowska-Wynimko J: miRNAs as biomarkers and therapeutic targets in non-small cell lung cancer: Current perspectives. Target Oncol. 12:179–200. 2017. View Article : Google Scholar : PubMed/NCBI
20	Wang N, Zhang Y and Liang H: microRNA-598 inhibits cell proliferation and invasion of glioblastoma by directly targeting metastasis associated in colon cancer-1. Oncol Res. Feb 14–2018.(Epub ahead of print). View Article : Google Scholar
21	Liu K, Sun X, Zhang Y, Liu L and Yuan Q: MiR-598: A tumor suppressor with biomarker significance in osteosarcoma. Life Sci. 188:141–148. 2017. View Article : Google Scholar : PubMed/NCBI
22	Chen J, Zhang H, Chen Y, Qiao G, Jiang W, Ni P, Liu X and Ma L: miR-598 inhibits metastasis in colorectal cancer by suppressing JAG1/Notch2 pathway stimulating EMT. Exp Cell Res. 352:104–112. 2017. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Cipollini M, Landi S and Gemignani F: Bonafide targets of deregulated microRNAs in non-small cell lung cancer as tool to identify novel therapeutic targets: A review. Curr Pharm Des. 23:55–72. 2017.PubMed/NCBI
25	Gao Y, Zhang W, Han X, Li F, Wang X, Wang R, Fang Z, Tong X, Yao S, Li F, et al: YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nat Commun. 5:46292014. View Article : Google Scholar : PubMed/NCBI
26	Hou Y, Zhen J, Xu X, Zhen K, Zhu B, Pan R and Zhao C: miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer. Oncol Lett. 10:1985–1992. 2015. View Article : Google Scholar : PubMed/NCBI
27	Jiao A, Sui M, Zhang L, Sun P, Geng D, Zhang W, Wang X and Li J: MicroRNA-200c inhibits the metastasis of non-small cell lung cancer cells by targeting ZEB2, an epithelial-mesenchymal transition regulator. Mol Med Rep. 13:3349–3355. 2016. View Article : Google Scholar : PubMed/NCBI
28	Cortinovis D, Monica V, Pietrantonio F, Ceresoli GL, La Spina CM and Wannesson L: MicroRNAs in non-small cell lung cancer: Current status and future therapeutic promises. Curr Pharm Des. 20:3982–3990. 2014. View Article : Google Scholar : PubMed/NCBI
29	Rolfo C, Fanale D, Hong DS, Tsimberidou AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, et al: Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. Curr Pharm Biotechnol. 15:475–485. 2014. View Article : Google Scholar : PubMed/NCBI
30	Tibaldi C, D'Incecco A and Lagana A: MicroRNAs and targeted therapies in non-small cell lung cancer: Minireview. Anticancer Agents Med Chem. 15:694–700. 2015. View Article : Google Scholar : PubMed/NCBI
31	Park SM, Gaur AB, Lengyel E and Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
32	Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y, Kinoshita K, Saito S, Baba Y and Baba H: MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol. 19 Suppl 3:S656–S664. 2012. View Article : Google Scholar : PubMed/NCBI
33	Chu PY, Hu FW, Yu CC, Tsai LL, Yu CH, Wu BC, Chen YW, Huang PI and Lo WL: Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer. Oral Oncol. 49:34–41. 2013. View Article : Google Scholar : PubMed/NCBI
34	Li MZ, Wang JJ, Yang SB, Li WF, Xiao LB, He YL and Song XM: ZEB2 promotes tumor metastasis and correlates with poor prognosis of human colorectal cancer. Am J Transl Res. 9:2838–2851. 2017.PubMed/NCBI
35	Sun DK, Wang JM, Zhang P and Wang YQ: MicroRNA-138 regulates metastatic potential of bladder cancer through ZEB2. Cell Physiol Biochem. 37:2366–2374. 2015. View Article : Google Scholar : PubMed/NCBI
36	Wang Q, Jiang H, Deng X, Fang W and Guo S: Expressions of ZEB2 and C-myc in epithelial ovarian cancer and their clinical significance. Nan Fang Yi Ke Da Xue Xue Bao. 35:1765–1769. 2015.(In Chinese). PubMed/NCBI
37	Prislei S, Martinelli E, Zannoni GF, Petrillo M, Filippetti F, Mariani M, Mozzetti S, Raspaglio G, Scambia G and Ferlini C: Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer. Oncotarget. 6:18966–18979. 2015. View Article : Google Scholar : PubMed/NCBI
38	Shi ZM, Wang L, Shen H, Jiang CF, Ge X, Li DM, Wen YY, Sun HR, Pan MH, Li W, et al: Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling. Oncogene. 36:2577–2588. 2017. View Article : Google Scholar : PubMed/NCBI
39	Fang S, Zeng X, Zhu W, Tang R, Chao Y and Guo L: Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer. Exp Mol Pathol. 96:438–444. 2014. View Article : Google Scholar : PubMed/NCBI
40	Lin X, Yang Z, Zhang P, Liu Y and Shao G: miR-154 inhibits migration and invasion of human non-small cell lung cancer by targeting ZEB2. Oncol Lett. 12:301–306. 2016. View Article : Google Scholar : PubMed/NCBI
41	Hong-Yuan W and Xiao-Ping C: miR-338-3p suppresses epithelial-mesenchymal transition and metastasis in human nonsmall cell lung cancer. Indian J Cancer. 52 Suppl 3:E168–E171. 2015. View Article : Google Scholar : PubMed/NCBI
42	Jiang M, Zhong T, Zhang W, Xiao Z, Hu G, Zhou H and Kuang H: Reduced expression of miR-205-5p promotes apoptosis and inhibits proliferation and invasion in lung cancer A549 cells by upregulation of ZEB2 and downregulation of erbB3. Mol Med Rep. 15:3231–3238. 2017. View Article : Google Scholar : PubMed/NCBI